| [1] |
Coley WB.The treatment of malignant tumors by repeated inoculations of erysipelas[J].Clin Orthop Relat Res,1991(262):3-11.
|
| [2] |
Wiemann B,Starnes CO.Coley′s toxins,tumor necrosis factor and cancer research:a historical perspective[J].Pharmacol Ther,1994,64(3):529-564.
|
| [3] |
Schreiber RD,Old LJ,Smyth MJ.Cancer immunoediting:integrating immunity′s roles in cancer suppression and promotion[J].Science,2011,331(6024):1565-1570.
|
| [4] |
Neller MA,Lopez JA,Schmidt CW.Antigens for cancer immunotherapy[J].Semin Immunol,2008,20(5):286-295.
|
| [5] |
Andersen BM,Ohlfest JR.Increasing the efficacy of tumor cell vaccines by enhancing cross priming[J].Cancer Lett,2012,325(2):155-164.
|
| [6] |
Li Y,Wang LX,Pang P,et al.Tumor-derived autophagosome vaccine:mechanism of cross-presentation and therapeutic efficacy[J].Clin Cancer Res,2011,17(22):7047-7057.
|
| [7] |
Twitty CG,Jensen SM,Hu HM,et al.Tumor-derived autophagosome vaccine:induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism[J].Clin Cancer Res,2011,17(20):6467-6481.
|
| [8] |
Ye W,Xing Y,Paustian C,et al.Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells[J].J Transl Med,2014,12:100.
|
| [9] |
Aspeslagh S,Postel S,Rusakiewicz S,et al.Rationale for anti-OX40 cancer immunotherapy[J].Eur J Cancer,2016,52:50-66.
|
| [10] |
Weixler B, Cremonesi E, Sorge R, et al. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer[J].Oncotarget,2015,6(35):37588-37599.
|
| [11] |
Brossart P,Grunebach F,Stuhler G,et al.Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor[J].Blood,1998,92(11):4238-4247.
|
| [12] |
Hanley PJ,Shaffer DR,Cruz CR,et al.Expansion of T cells targeting multiple antigens of cytomegalovirus,epstein-barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation[J].Cytotherapy,2011,13(8):976-986.
|
| [13] |
Paustian C,Caspell R,Johnson T,et al.Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells[J].Hum Immunol,2011,72(1):24-31.
|
| [14] |
Chen L,Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
|
| [15] |
Nowicki TS,Anderson JL,Federman N.Prospective immunotherapies in childhood sarcomas:PD1/PDL1 blockade in combination with tumor vaccines[J].Pediatr Res,2016,79(3):371-377.
|
| [16] |
Guilleminault L,Carmier D,Heuze N,et al.Immunotherapy in non-small cell lung cancer:inhibition of PD1/PDL1 pathway[J].Rev Pneumol Clin,2015,71(1):44-56.
|
| [17] |
Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3-potential mechanisms of action[J].Nat Rev Immunol,2015,15(1):45-56.
|
| [18] |
Ascierto PA,Marincola FM,Ribas A.Anti-CTLA4 monoclonal antibodies:the past and the future in clinical application[J].J Transl Med,2011,9:196.
|
| [19] |
Zehner M,Marschall AL,Bos E,et al.The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+)T cells[J].Immunity,2015,42(5):850-863.
|
| [20] |
Munz C. Of LAP, CUPS, and DRibbles-unconventional use of autophagy proteins for MHC restricted antigen presentation[J].Front Immunol,2015,6:200.
|
| [21] |
Yi Y,Zhou Z,Shu S,et al.Autophagy-assisted antigen cross-presentation:autophagosome as the argo of shared tumor-specific antigens and DAMPs[J].Oncoimmunology,2012,1(6):976-978.
|
下载:
